<em>In vitro</em> and <em>in vivo</em> efficacy of Molnupiravir against Zika virus infections

Zhuang Wang; Shaokang Yang; Qingsong Dai; Xiaojia Guo; Yuexiang Li; Wei Li; Xiaotong Yang; Jingjing Yang; Xintong Yan; Huimin Tao; Chongda Luo; Song Li; Xingjuan Chen; Ruiyuan Cao; Wu Zhong

doi:10.1016/j.virs.2023.05.011

August 2023

. doi: 10.1016/j.virs.2023.05.011

Citation: Zhuang Wang, Shaokang Yang, Qingsong Dai, Xiaojia Guo, Yuexiang Li, Wei Li, Xiaotong Yang, Jingjing Yang, Xintong Yan, Huimin Tao, Chongda Luo, Song Li, Xingjuan Chen, Ruiyuan Cao, Wu Zhong. In vitro and in vivo efficacy of Molnupiravir against Zika virus infections .VIROLOGICA SINICA, 2023, 38(4) : 639-642. http://dx.doi.org/10.1016/j.virs.2023.05.011

莫那匹韦对寨卡病毒感染的体内外疗效

王壮 ^a,b ,
杨绍康 ^b,c ,
代青松 ^b ,
郭小家 ^b ,
李月香 ^b ,
李微 ^b ,
杨晓童 ^b,e ,
杨晶晶 ^b,d ,
闫鑫彤 ^b,d ,
陶慧敏 ^b,e ,
罗崇达 ^b,d ,
李松 ^b,d ,
陈兴娟 ^a,, ,
曹瑞源 ^b,, ,
钟武 ^b,,

西北工业大学医学研究院, 中国西安;国家应急防控药物中心, 中国北京;河北科技大学化学与制药工程学院, 中国石家庄;海南大学药学院李松院士工作站, 中国三亚崖州湾;清华大学医学院, 中国北京

通讯作者： 陈兴娟, xjchen@nwpu.edu.cn; 曹瑞源, 21cc@163.com; 钟武, zhongwu@bmi.ac.cn
收稿日期： 2023-01-05
录用日期： 2023-05-30

摘要

寨卡病毒是一种被广泛关注的黄病毒，具有全球大流行的潜力，可引起严重的神经系统疾病。莫那匹韦（EIDD-2801）已被证明对多种高致病性RNA病毒具有有效的体内外活性，并在美国、英国和中国等国家批准用于治疗SARS-CoV-2。它有可能在当前和未来流行性病中成为重要的口服抗病毒药物。然而，莫那匹韦对寨卡病毒的疗效尚未得到确认。本研究以EIDD-2801的体内代谢形式EIDD-1931进行细胞水平抗病毒研究，并以EIDD-2801/1931进行体内抗寨卡病毒活性评价。结果表明，EIDD-2801和EIDD-1931具有广谱抗黄病毒作用。此外，EIDD-1931剂量依赖性地抑制子代病毒颗粒、病毒RNA和病毒蛋白的产生。腹腔注射EIDD-2801/1931可保护1日龄ICR小鼠免受ZIKV致死性攻击。通过加药时序实验和ZIKV复制子抑制实验，我们发现EIDD-1931可能通过抑制寨卡病毒的复制阶段从而发挥抗病毒活性。我们的研究结果将黄病毒添加到莫那匹韦的抗病毒谱中，它极有可能成为抗黄病毒感染(包括ZIKV)的有效候选抗病毒药物。
- 寨卡病毒
- , 莫那匹韦
- , 病毒复制

In vitro and in vivo efficacy of Molnupiravir against Zika virus infections

Zhuang Wang ^a,b ,
Shaokang Yang ^b,c ,
Qingsong Dai ^b ,
Xiaojia Guo ^b ,
Yuexiang Li ^b ,
Wei Li ^b ,
Xiaotong Yang ^b,e ,
Jingjing Yang ^b,d ,
Xintong Yan ^b,d ,
Huimin Tao ^b,e ,
Chongda Luo ^b,d ,
Song Li ^b,d ,
Xingjuan Chen ^a,, ,
Ruiyuan Cao ^b,, ,
Wu Zhong ^b,,

a. Institute of Medical Research, Northwestern Polytechnical University, Xi'an, 710072, China;
b. National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China;
c. College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, 050018, China;
d. Song Li's Academician Workstation of Hainan University (School of Pharmaceutical Sciences), Yazhou Bay, Sanya, 572000, China;
e. School of Medicine, Tsinghua University, Beijing, 100084, China

Corresponding author: Xingjuan Chen, xjchen@nwpu.edu.cn Ruiyuan Cao, 21cc@163.com Wu Zhong, zhongwu@bmi.ac.cn
Received Date: 05 January 2023
Accepted Date: 30 May 2023

Abstract

Highlights
1. Molnupiravir exhibits effective antiviral activity against ZIKV in vitro.
2. Intraperitoneal administration of Molnupiravir protects mice from lethal ZIKV challenge.
3. Molnupiravir might act on the replication phase of the ZIKV life cycle.

References
1. Barzon, L., Pacenti, M., Franchin, E., Lavezzo, E., Trevisan, M., Sgarabotto, D., Palù, G., 2016. Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016. Euro surveillance. 21, 30316.
2. Bluemling, G.R., Mao, S., Natchus, M.G., Painter, W., Mulangu, S., Lockwood, M., De La Rosa, A., Brasel, T., Comer, J.E., Freiberg, A.N., Kolykhalov, A.A., Painter, G.R., 2022. The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N(4)-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection. Antiviral research. 209, 105453.
3. Cugola, F.R., Fernandes, I.R., Russo, F.B., Freitas, B.C., Dias, J.L., Guimarães, K.P., Benazzato, C., Almeida, N., Pignatari, G.C., Romero, S., Polonio, C.M., Cunha, I., Freitas, C.L., Brandão, W.N., Rossato, C., Andrade, D.G., Faria Dde, P., Garcez, A.T., Buchpigel, C.A., Braconi, C.T., Mendes, E., Sall, A.A., Zanotto, P.M., Peron, J.P., Muotri, A.R., Beltrão-Braga, P.C., 2016. The Brazilian Zika virus strain causes birth defects in experimental models. Nature. 534, 267-271.
4. Faye, O., Freire, C.C., Iamarino, A., Faye, O., de Oliveira, J.V., Diallo, M., Zanotto, P.M., Sall, A.A., 2014. Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS neglected tropical diseases. 8, e2636.
5. Lessler, J., Chaisson, L.H., Kucirka, L.M., Bi, Q., Grantz, K., Salje, H., Carcelen, A.C., Ott, C.T., Sheffield, J.S., Ferguson, N.M., Cummings, D.A., Metcalf, C.J., Rodriguez-Barraquer, I., 2016. Assessing the global threat from Zika virus. Science. 353, aaf8160.
6. Li, J.Q., Deng, C.L., Gu, D., Li, X., Shi, L., He, J., Zhang, Q.Y., Zhang, B., Ye, H.Q., 2018. Development of a replicon cell line-based high throughput antiviral assay for screening inhibitors of Zika virus. Antiviral research. 150, 148-154.
7. Li, Y., Liu, M., Yan, Y., Wang, Z., Dai, Q., Yang, X., Guo, X., Li, W., Chen, X., Cao, R., Zhong, W., 2022. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo. Viruses. 14, 1142.
8. Nicastri, E., Castilletti, C., Liuzzi, G., Iannetta, M., Capobianchi, M.R., Ippolito, G., 2016. Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. Euro surveillance. 21, 30314.
9. Nie, Y., Hui, L., Guo, M., Yang, W., Huang, R., Chen, J., Wen, X., Zhao, M., Wu, Y., 2021. Rearrangement of Actin Cytoskeleton by Zika Virus Infection Facilitates Blood-Testis Barrier Hyperpermeability. Virologica Sinica 36, 692-705.
10. Pacheco, O., Beltrán, M., Nelson, C.A., Valencia, D., Tolosa, N., Farr, S.L., Padilla, A.V., Tong, V.T., Cuevas, E.L., Espinosa-Bode, A., Pardo, L., Rico, A., Reefhuis, J., González, M., Mercado, M., Chaparro, P., Martínez Duran, M., Rao, C.Y., Muñoz, M.M., Powers, A.M., Cuéllar, C., Helfand, R., Huguett, C., Jamieson, D.J., Honein, M.A., Ospina Martínez, M.L., 2020. Zika Virus Disease in Colombia-Preliminary Report. The New England journal of medicine. 383, e44.
11. Rosenke, K., Okumura, A., Lewis, M.C., Feldmann, F., Meade-White, K., Bohler, W.F., Griffin, A., Rosenke, R., Shaia, C., Jarvis, M.A., Feldmann, H., 2022. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model. JCI insight. 7, e160108.
12. Sargent, K., Mollard, J., Henley, S.F., Bollasina, M.A., 2022. Predicting Transmission Suitability of Mosquito-Borne Diseases under Climate Change to Underpin Decision Making. International journal of environmental research and public health. 19, 13656.
13. Toots, M., Yoon, J.J., Cox, R.M., Hart, M., Sticher, Z.M., Makhsous, N., Plesker, R., Barrena, A.H., Reddy, P.G., Mitchell, D.G., Shean, R.C., Bluemling, G.R., Kolykhalov, A.A., Greninger, A.L., Natchus, M.G., Painter, G.R., Plemper, R.K., 2019. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science translational medicine. 11, eaax5866.
14. Voordouw, B., Rockx, B., Jaenisch, T., Fraaij, P., Mayaud, P., Vossen, A., Koopmans, M., 2019. Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays. Clinical microbiology reviews. 33, e00130-18.
15. Wang, H., Li, Z., Niu, J., Xu, Y., Ma, L., Lu, A., Wang, X., Qian, Z., Huang, Z., Jin, X., Leng, Q., Wang, J., Zhong, J., Sun, B., Meng, G., 2018. Antiviral effects of ferric ammonium citrate. Cell discovery 4, 14.
16. Wang, Q., Cao, R., Li, L., Liu, J., Yang, J., Li, W., Yan, L., Wang, Y., Yan, Y., Li, J., Deng, F., Zhou, Y., Wang, M., Zhong, W., Hu, Z., 2022a. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus. Antiviral research. 199, 105273.
17. Wang, Z., Yan, Y., Dai, Q., Xu, Y., Yin, J., Li, W., Li, Y., Yang, X., Guo, X., Liu, M., Chen, X., Cao, R., Zhong, W., 2022b. Azelnidipine Exhibits In Vitro and In Vivo Antiviral Effects against Flavivirus Infections by Targeting the Viral RdRp. Viruses. 14, 1228.
18. WHO, 2022. Zika epidemiology update-February 2022. https://www.who.int/publications/m/item/zika-epidemiology-update-february-2022 (Accessed 21 April 2023)
19. Wikan, N., Smith, D.R., 2016. Zika virus:history of a newly emerging arbovirus. The Lancet. Infectious diseases. 16, e119-e126.
20. Yan, Y., Yang, J., Xiao, D., Yin, J., Song, M., Xu, Y., Zhao, L., Dai, Q., Li, Y., Wang, C., Wang, Z., Ren, X., Yang, X., Ni, J., Liu, M., Guo, X., Li, W., Chen, X., Liu, Z., Cao, R., Zhong, W., 2022. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins. Antiviral research. 202, 105325.
21. Yang, J., Yan, Y., Dai, Q., Yin, J., Zhao, L., Li, Y., Li, W., Zhong, W., Cao, R., Li, S., 2022. Tilorone confers robust in vitro and in vivo antiviral effects against severe fever with thrombocytopenia syndrome virus. Virologica Sinica. 37, 145-148.
Proportional views
Electronic Supplementary Material

10.1016j.virs.2023.05.011-ESM.docx